Lupin launches long-acting Risperidone in US
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
FIBROSARC did not meet its primary PFS endpoint in the final analysi
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Subscribe To Our Newsletter & Stay Updated